Yttrium (<sup>90</sup>Y) tacatuzumab tetraxetan is an investigational humanized monoclonal antibody intended for the treatment of cancer. The antibody itself, tacatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells.